Email
Print
Decongestants Market Overview
The Decongestants Market size is estimated to reach $21.3 billion by 2027, growing at an estimated CAGR of 6.3% during the forecast period 2022-2027. Decongestants or nasal decongestants constitute a kind of pharmaceutical medication that is utilized to alleviate nasal congestion in the upper respiratory tract. North America held the largest Decongestants Market share with 40% of the overall market in 2021. The effective constituent in nearly all decongestants is either pseudoephedrine or phenylephrine with questionable efficiency. Numerous independent investigations suggested that it offered no more alleviation to sinus congestion than a placebo. Intranasal corticosteroids can also be utilized as decongestants and antihistamines can be utilized to relieve runny noses, nasal itch and sneezing. Loss of smell is termed anosmia or impaired smell. Anosmia treatment includes options like decongestants and antihistamines steroids and surgery.
Decongestants (like Sudafed or any medicine with pseudoephedrine) diminish blood vessels in the mucous membranes, specifically in the sinuses, lessening mucus generation. They perform best for nasal congestion. Decongestants decrease nasal congestion. However, they have no additional important impacts on the symptoms of rhinitis. Nearly all the eicosanoid receptors are basic membrane protein G protein-coupled receptors (GPCRs) that bind and respond to eicosanoid signaling molecules. Eicosanoids are very quickly metabolized to inert products and thus are short-lived. The increasing count of cases of cold & flu in winter is set to drive the Decongestants Market. This represents the Decongestants Industry Outlook.
Decongestants Market Report Coverage
The “Decongestants Market Report
- Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the
following segments in the Decongestants
Market.
Key Takeaways
- Geographically, North America (Decongestants Market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the soaring sales of decongestants (which may include pseudoephedrine or phenylephrine) and the surging application of over-the-counter ocular decongestants for handling ocular redness in the U.S.
- Decongestants Market growth is being driven by the surging application of decongestants and antihistamines in the treatment of nasal congestion and alleviating systems connected with hay fever, sinusitis and colds & flu. However, decongestants may generate side effects like Central Nervous System (CNS) Stimulation and may not be appropriate for people with heart diseases, high blood pressure or urinary issues and for someone who consumes some medicines like monoamine oxidase inhibitors. These are some of the major factors hampering the growth of the Decongestants Market.
- Decongestants Market Detailed Analysis of the Strength, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Decongestants Market report.
Decongestants Market: Market Share (%) by Region, 2021
For More Details On this report - Request For Sample
Decongestants Market Segment Analysis - by Type
The Decongestants Market based
on type can be further segmented into Tablets, Capsules and Nasal Sprays. The Tablets Segment held the largest Decongestants Market share
in 2021. This growth is fuelled by the surging application of decongestant
tablets to alleviate stuffy nose, sinus and ear congestion symptoms. Acetaminophen
(APAP) is a non-aspirin pain reliever and fever reducer. Antihistamines assist
in alleviating watery eyes, itchy eyes/nose/throat, runny nose and sneezing. The
extensive application of oral decongestants to decrease congestion in the
treatment of Allergic Rhinitis is further propelling the growth of the Tablets segment.
Furthermore, the Nasal Sprays segment is estimated to grow with the
fastest CAGR of 7.1% during the forecast period 2022-2027 due to the surging application of nasal sprays for treating cases of excessive mucus, common cold,
rhinitis and hay fever. The benefits of nasal spray like easier use and faster performance are also contributing factors.
Decongestants Market Segment Analysis - by Application
The Decongestants Market
based on the application can be further segmented into Hospitals, Clinics, Research & Academic Laboratories and others. The Hospitals Segment held the largest Decongestants Market share in 2021. This growth is driven by the increasing
inclination of patients toward hospitals for diagnosis of conditions like cold
allergies, hay fever, rhinitis and sinusitis. Decongestant nose drops are frequently
prescribed to offer instant relief in conditions like the common cold,
Sinusitis and Allergic Rhinitis. The presence of advanced infrastructure and
the easy availability of qualified & skilled physicians and
multidisciplinary teams in hospitals are further propelling the growth of this
segment.
Furthermore, the Clinics segment is estimated
to grow with the fastest CAGR of 7.3% during the forecast period 2022-2027 owing to the extensive
prescription of decongestants which may include pseudoephedrine or phenylephrine.
Decongestants Market Segment Analysis - by Geography
The Decongestants Market
based on geography can be further segmented into North America, Europe,
Asia-Pacific, South America and the Rest of the World. North America (Decongestants
Market) held the largest market share with 40% of the overall market in
2021. The growth of this region is driven by the existence of countries
like the U.S. and Canada which contribute considerably to the revenues in the North
American region. Anosmia is a condition that includes a total
loss of smell affecting nearly 3-20% of people. Corticosteroids or surgery
may be the alternatives for those having anosmia owing to sinonasal ailment. The
existence of key players like Mylan N.V. in the U.S. in North America is further
propelling the growth of the Decongestants Industry, thereby contributing to
the Decongestants Industry Outlook in the North American region.
Furthermore, the Asia-Pacific region is estimated to grow with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the surging application of decongestants for alleviating symptoms of nasal congestion in the Asia-Pacific region. The soaring inclination towards nasal sprays due to their effortless administration and the increasing count of cases of Anosmia are further fuelling the progress of the Decongestants Market in the Asia-Pacific region.
Decongestants Market Drivers
Surging Applications of Decongestants are Projected to Drive the Growth of the Decongestants Market:
Intranasal corticosteroids (INCS) constitute the most efficient medication for treating chronic rhinitis. Intranasal corticosteroids may also be utilized as decongestants, while antihistamines should be utilized to relieve conditions like runny nose, nasal itch and sneezing. Nearly all decongestants perform by activating alpha-adrenergic receptors either by binding directly to them or prompting the discharge of norepinephrine, a chemical transmitter. Activation of these receptors brings about vasoconstriction (a narrowing of the blood vessels inside that area). This reduces blood flow and assists in decreasing swollen tissue, alleviating congestion. They are frequently utilized in integration with antihistamines. Topical decongestants on topical utilization as a dilute solution (0.05–0.1%) generate local vasoconstriction. The surging applications of decongestants are therefore fuelling the growth of the Decongestants Market during the forecast period 2022-2027.
Soaring Innovative Decongestants are Expected to Boost the Growth of the Decongestants Industry:
With regard to decongestants, as per the Multum Therapeutic Class Comparison (the US, 2019), the total prescriptions in 2019 pertaining to Pseudoephedrine were 555,202 and those pertaining to Phenylephrine were 50,833 with a percentage share of 91.6% and 8.4%, respectively. GoodSense Phenylephrine HCL Nasal Decongestant Tablets feature in the list of the “Top 10 Decongestants of 2022”. The active constituent in GoodSense Maximum Strength Nasal Decongestant PE is phenylephrine HCl 10 mg, a nasal decongestant, which is comparable to the active constituent in Sudafed PE Congestion. This product is a nasal decongestant that offers maximum strength and non-drowsy alleviation for nasal & sinus congestion and sinus pressure owing to the common cold, hay fever or additional upper respiratory allergies. GoodSense Maximum Strength Nasal Decongestant PE offers utmost strength alleviation for sinus pressure, nasal and sinus congestion. Non-drowsy alleviation keeps one powered up all through the day. GoodSense Maximum Strength Nasal Decongestant PE (Phenylephrine HCl, 10 mg) does not include pseudoephedrine. These kinds of increasingly popular innovative decongestants are therefore driving the growth of the Decongestants Industry, thereby contributing to the Decongestants Industry Outlook during the forecast period 2022-2027.
Decongestants Market Challenge:
Limitations of Decongestants are Hampering the Growth of the Decongestants Market:
Decongestants are contraindicated in patients with serious hypertension, coronary artery disease (CAD), narrow-angle glaucoma and certain antidepressant application. It needs to be utilized with caution in patients who have cardiac dysrhythmias, hyperthyroidism, DM (diabetes mellitus), prostatic hypertrophy and glaucoma. Utilizing nasal decongestants frequently and for more than three to five days has been connected with rebound congestion. This is when nasal congestion recurs almost instantly once the application of the decongestant is halted, propelling repeat application of the nasal decongestant. Nearly all investigations left out children. Thus, nearly all experts suggest not providing decongestants to children under the age of 12 owing to their efficiency and risk of side effects being unrecognized. Certain decongestants (like pseudoephedrine) have been connected with heart-related side effects like inflated blood pressure, palpitations and tachycardia. These issues are thus hampering the growth of the Decongestants Market.
Decongestants Industry Outlook
Novel product launches, mergers and acquisitions, partnerships, agreements, collaborations, joint ventures, regional expansions and R&D activities are key strategies adopted by players in the Decongestants Market. The top 10 companies in the Decongestants Market are:
- Beximco Pharmaceuticals Ltd.
- Sandoz International GmbH (Novartis AG)
- Cipla Ltd.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Ranbaxy Laboratories Ltd.
- Panadol
- SUDAFED
- Vicks (Procter & Gamble · Helen of Troy Limited)
- Smart Sense
Recent Developments
- In March 2022, Sandoz, a Novartis division, declared that it had favorably gained the UK-based medical and drug delivery device development firm, Coalesce Product Development Limited. By way of this deal, Sandoz has gained the considerable capabilities and assets of Coalesce, which would assist it in expanding its existing portfolio of respiratory medications. This would further enhance patient access to these high-quality, complicated therapies.
- In October 2021, Sandoz, a Novartis division, favorably finished the acquisition of GSK’s cephalosporin antibiotics business. By way of this transaction, Sandoz has gained rights to three well-established brands (Zinnat, Zinacef and Fortum) in more than 100 markets, further strengthening its chief global position in antibiotics.
- In October 2021, Beximco Pharmaceuticals Limited completed its acquisition of the majority stake (54.6%) in Sanofi Bangladesh Limited.
Relevant Reports:
Report Code: HCR 0111
Report Code: HCR 0066
Report Code: HCR 0372